Therefore, the current study was designed to detect the FANCD2 mutation in AP-CML (early progression phase) patients and to investigate and clinically validate its potential as a novel biomarker of early CML progression from CP to AP. The gene discussed is FANCD2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.